Strategic approaches to developing drug treatments for ALS. - Wikidata - wikimedia - TriplyDB

Strategic approaches to developing drug treatments for ALS.

Strategic approaches to developing drug treatments for ALS.

http://www.wikidata.org/entity/Q36485321

about

Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis Emerging from the bottleneck: benefits of the comparative approach to modern neuroscience Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis New therapeutic targets for amyotrophic lateral sclerosis.Potential new complication in drug therapy development for amyotrophic lateral sclerosis.Potential for promoting recurrent laryngeal nerve regeneration by remote delivery of viral gene therapy.Mouse models of Huntington disease: variations on a theme.A chemical chaperone-based drug candidate is effective in a mouse model of amyotrophic lateral sclerosis (ALS).Optimization of immunosuppressive therapy for spinal grafting of human spinal stem cells in a rat model of ALS.

P2860

Q24655277-0DB9E055-9061-47E3-B5EE-8E48C1A2F0CB Q28083884-7D76926A-155F-4232-AC5E-898C520B464F Q33670805-6DCAA58E-D556-4333-8337-E546D567115B Q35156359-292FF27E-FDE6-459A-9069-316979549A72 Q37816447-B537EF2A-DC11-475F-8659-068052F32CE5 Q38881707-62E94EEC-50C3-49FE-B9FB-0915D8D92CF6 Q39664862-41AE255B-C9AF-47DE-90BA-5A50677A7758 Q42155772-B18F2C5E-32E6-496C-9243-38FF9632613F Q50438014-5ADC5F24-B83B-485C-911B-1CD82C36EA43 Q51450955-74C279AF-FC0A-4F35-8B97-AA8ECFC75507

P2860

Strategic approaches to developing drug treatments for ALS.

http://www.wikidata.org/entity/Q36485321

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Strategic approaches to developing drug treatments for ALS.

@ast

Strategic approaches to developing drug treatments for ALS.

@en

type

label

Strategic approaches to developing drug treatments for ALS.

@ast

Strategic approaches to developing drug treatments for ALS.

@en

prefLabel

Strategic approaches to developing drug treatments for ALS.

@ast

Strategic approaches to developing drug treatments for ALS.

@en

P1433

Q36485321-A60B7861-1D78-4BB7-9B20-444871BEF556

P1476

Q36485321-6F127DDF-5C62-44DA-B411-6ECB09A92E74

P2093

Q36485321-33DDF5AB-9376-47A4-A8D4-91084069622E

Q36485321-D320621D-7BCC-4E25-A5F8-686B5BC2511B

P2860

Q36485321-045B7726-3474-4488-804E-21D7E5A1871C

Q36485321-072320C0-FDF6-4BD1-B90F-D732FF6C2085

Q36485321-09889A5B-521E-436C-8473-0B3CE358D198

Q36485321-0B64FA5E-F526-4436-B5C5-B9695164B879

Q36485321-12E6723A-B0E4-4024-BFCB-EB24422458C1

Q36485321-143563AF-8A5A-45A1-8A5C-9DAAE8E1A9D6

Q36485321-1865B5C6-5A43-4627-8EE5-BA058742E97E

Q36485321-1BA71E3F-3F6B-4906-9A21-5050C630DA6C

Q36485321-1EACBA78-DE0A-4D30-9173-0246A218CA14

Q36485321-20A01DCC-A07E-4A3A-83E7-D82B43DB0E39

P304

Q36485321-928195D1-4FCA-4374-9F57-685D8EF54EAB

P31

Q36485321-DC6B1452-BD93-4C29-BA13-07620EE26F63

P356

Q36485321-A2EB769C-5632-4BB8-B91E-2F14E7D26979

P433

Q36485321-A7F2BB63-3065-40CD-8986-64E31CC299E1

P478

Q36485321-DE36F3D7-0381-419F-BCED-CB1AB079E258

P50

Q36485321-75C287C0-1413-4FB7-8980-A8D96693296A

Q36485321-C9CBF309-1D1C-4930-8212-07217B7CD150

P577

Q36485321-986D7D29-51E0-4CA9-9E76-7C4B9D4A5F5F

P5875

Q36485321-61C21FF9-6471-4E4B-8346-911DAE78A61B

P698

Q36485321-A423934C-E3AA-4B73-AE04-2B55CD5B60DE

P921

Q36485321-88D2A543-004C-4578-BDED-01C7DB33E384

P932

Q36485321-1B66127A-1A86-4F8D-8EE8-26C00596CDB3

P356

J.DRUDIS.2007.10.011

P1433

Drug Discovery Today

P1476

Strategic approaches to developing drug treatments for ALS

@en

P2093

Andrea M Vincent

http://www.w3.org/2001/XMLSchema#string

Stacey A Sakowski

http://www.w3.org/2001/XMLSchema#string

P2860

How common are the "common" neurologic disorders?

Familial amyotrophic lateral sclerosis/motor neurone disease (FALS): a review of current developments

Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis

Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons

ALS: a disease of motor neurons and their nonneuronal neighbors

Unraveling the mechanisms involved in motor neuron degeneration in ALS

Onset and progression in inherited ALS determined by motor neurons and microglia

Pathogenic superoxide dismutase structure, folding, aggregation and turnover.

P304

67-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUDIS.2007.10.011

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Adam D Schuyler

P577

2007-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5660385

http://www.w3.org/2001/XMLSchema#string

P698

18190866

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

2259461

http://www.w3.org/2001/XMLSchema#string